I-Interferon yilisiza esichaza iprotheni emzimbeni ukuba isistim somzimba sisebenzise ukutshabalalisa iintsholongwane. I-intergyon ye-Pegylated yindlela eguqulelweyo yeziyobisi ekwazi ukuhlala emzimbeni ixesha elide, elinika unyango olungcono. I-Polyethylene glycol (PEG) yongezwa kwi-interferon, inkqubo ebizwa ngokuba yi-pegylation, esetyenziswa kunye nezinye iintlobo zamachiza.
Iindidi ezimbini ze-intergyon ze-pegylated zikhoyo kwaye zisetyenziselwa ukunyanga ukusuleleka kwintsholongwane ka- Hepatitis C.
- I-Peginterferon alfa-2a: Ebizwa ngokuba yi-alfa-2a, igama loshishino uPegasys.
- I-Peginterferon alfa-2b: Ebizwa ngokuba yi-alfa-2b, igama loshishino uPegIntron.
Babecatshangwa unyango olukhethiweyo, olusetyenziswe ne ribavirin, kwaye ludweliswe kwiLuhlu lwezeMpilo yeSizwe lweeMfuno ezibalulekileyo. Ukunyangwa kwe-HCV kutshintsha ngokuvunyelwa kweSofosbuvir (Sovaldi) kunye neSimeprevir (i-Olysio) ngo-2013 yi-FDA. La machiza amasha kunye nabanye abaqinisekileyo ukuba bawalandele bangasusa i-peginterferons njengonyango olukhethiweyo.
Umehluko omkhulu phakathi kwala ma-interferons e-pegylated e-dosing. I-Alfa-2a isetyenziswe njengedayiti ehleliweyo yeveki nganye. I-Alfa-2b isetyenziswe njengedoloji yeveki esekelwe kwisisindo somguli. Kukho ezinye iintlukwano phakathi kwezi mbini, kodwa zizinto zobugcisa kwaye zisetyenziswe ngunyango .
Ngokomzekelo, i-alfa-2a ine-absorption eqhubekayo emva kokujova kwaye isasazwa kakhulu kwigazi nakwamalungu. Kodwa i-alfa-2b ine-absorption ngokukhawuleza kunye nokwabiwa ngokubanzi emzimbeni.
Ulwahlulo kwiNtsebenzo
Kude ngoJanuwari 2008, akukho datha ngokuthe ngqo ngokuthelekisa la mayeza amabini. Oku kutshintshile ngophando olukhulu lwekliniki ebizwa ngokuba yi-IDEAL kunye nokuthelekiswa klinikhi.
Ezi zibonelela ngeziphumo ezithandekayo eziza kuvumela oogqirha ukuba baqikelele ngakumbi kwezi zifo zonyango ezingapheliyo ze- hepatitis C.
Ucwaningo lwe-IDEAL - I-Personal Dosing Efficiency ngokubhekiselele kwi-Flat Dosing yokuHlola i-Optimal Pegylated Treatment ye-Interferon-yabandakanya abantu abangama-3070 kwiilingo ezilawulwa ngokungahleliwe. Kufumene ukuphumelela okufanayo phakathi kwe-alfa-2a kunye ne-alfa-2b kwisilinganiselo sokuphendula esilondolozo . I-Alfa-2a inomlinganiselo we-41% kunye ne-alfa-2b ine-SVR ye-39%.
Kodwa ityala alizange livaliwe. Uphando olongezelelweyo oluninzi lufumene ulwahlulo olubalulekayo phakathi kwamachiza amabini, kunye ne-alfa-2a ngokuphumelelayo ngokuphumelelayo ngamanani angaphezulu kwama-12% angcono kwi-SVR.
Olunye uhlalutyo lweemeta ezingama-3518 kwizigulane ezisixhenxe ezilawulwa ngandlela-thile zifumene iziphumo ezingcono nge-alfa-2a, nangona ivelise izinga eliphezulu le-neutropenia. I-Neutropenia ukunciphisa kwinani lamaseli egazi ezimhlophe. Lo mphumo wecala ongeyithandekayo, njengeeseli ezimhlophe zegazi ziyinxalenye enkulu ye-system immune system. Xa kuncitshisiwe, uya kuba sengozini yokusuleleka kwaye ungakwazi ukulwa neebhaktheriya kunye neentsholongwane.
Ezi ziphumo ziyakuthi ziqwalaselwe xa zicebisa unyango. Kodwa ukunyanga okutsha kunokususa i-peginterferons njengonyango olukhethiweyo lwe-hepatitis C. engapheliyo.
Unjalo uhlobo lophando nophuhliso. Ekugqibeleni kuya kubakho ukuqhathanisa ukuthelekisa la mayeza amabini njengonyango olutsha luya kukhethwa.
Imithombo:
Berenguer M, Wright TL. I-Hepatitis C. Ku: M Feldman, uLS Friedman, uLJ Brandt (eds), izifo zesisu kunye nezifo zesifo, 8e . Philadelphia, Elsevier, 2006. 1701.
Imibuzo ye-Hepatitis C kwi-Health Professionals, ngo-Oktobha 14, 2015. Iziko zokuLawula nokuLawulwa kwezifo
McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD , I-Brass CA, i-Albrecht JK, iSulkowski MS, iQela lokuFunda le-IDEAL. I-Peginterferon alfa-2b okanye i-alfa-2a ne-ribavirin unyango lwe-hepatitis C. N Engl J Med. 2009; 361 (6): 580-93.
Rumi MG, Aghemo A, Prati GM, D'Ambrosio R, Donato MF, Soffredini R, Del Ninno E, Russo A, Colombo M. Ukufundisisa nge-peginterferon-alpha2a kunye nerbavirin vs peginterferon-alpha2b kunye ne-ribavirin kwi-hepatitis C. engapheliyo I- Gastroenterology . 2010; 138 (1): 108-15.
I-Ascione A, De Luca M, iTartaglione MT, iLampasi F, i-Di Costanzo GG, i-Lanza AG, i-Picciotto FP, i-Marino-Marsilia G, i-Fontanella L, i-Leandro G. i-Peginterferon i-alfa-2a kunye ne-ribavirin iyasebenza ngakumbi kune-peginterferon alfa-2b kunye nerbavirin ukuphelisa intsholongwane engapheliyo yesifo se-hepatitis C. Gastroenterology . 2010; 138 (1): 116-22.
Alavian SM, Behnava B, Tabatabaei SV. Ukusebenza okuthelekisayo kunye nokukhuselwa kwe-peginterferon i-alpha-2a vs 2b yokunyangwa kwe-HCV yokungapheliyo: uhlalutyo lwe-meta. Hepat Mon. 2010; 10 (2): 121-31.